ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 0517 • ACR Convergence 2023

    Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?

    Casper Webers1, Rabab Nezam El-Din1, Marin Been1, Harald Vonkeman2 and Astrid van Tubergen1, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, 2Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands

    Background/Purpose: In patients with axial spondyloarthritis (axSpA) and high disease activity (typically defined as Ankylosing Spondylitis Disease Activity Score [ASDAS]≥2.1), it is recommended to adapt…
  • Abstract Number: 0832 • ACR Convergence 2023

    Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry

    William Soulsby, Erica Lawson, John Boscardin and Emily von scheven, University of California San Francisco, San Francisco, CA

    Background/Purpose: The impact of race and social determinants of health (SDoH) on health outcomes in juvenile idiopathic arthritis (JIA) remains poorly understood. Prior disparities research…
  • Abstract Number: 1063 • ACR Convergence 2023

    Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

    Jenny Li1, Marie Hudson2, Carrie Ye3, Janet Roberts4, Aurore Fifi-Mah5, May Choi5, Sabrina Hoa6, Thomas Appleton7, Janet Pope7, Nancy Maltez8, Lourdes Gonzalez Arreola9, Anthony Obrzut9 and Shahin Jamal10, 1University of British Columbia, Vancouver, BC, Canada, 2McGill University, Montréal, QC, Canada, 3University of Alberta, Edmonton, AB, Canada, 4Dalhousie University, Halifax, NS, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Montreal, Brossard, QC, Canada, 7University of Western Ontario, London, ON, Canada, 8The Ottawa Hospital, Ottawa, ON, Canada, 9Arthritis Research Canada, Vancouver, BC, Canada, 10Vancouver Coastal Health, Vancouver, BC, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…
  • Abstract Number: 1361 • ACR Convergence 2023

    Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers

    Takehiro Nakai1, Nanase Honda2, Sho Fukui3, Ayako Kitada1, Naoto Yokogawa4 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, 3Brigham and Women's Hospital, Boston, MA, 4Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan

    Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
  • Abstract Number: 1448 • ACR Convergence 2023

    Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

    Natalia Guajardo-Jauregui1, Iris Colunga2, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is…
  • Abstract Number: 1905 • ACR Convergence 2023

    Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic

    Rumey Ishizawar1, Thuyvan Phan2 and Steven Takacs3, 1University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, 2University of North Carolina Hospitals Department of Pharmacy, Apex, NC, 3University of North Carolina Faculty Physicians, Chapel Hill, NC

    Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
  • Abstract Number: 2264 • ACR Convergence 2023

    Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes

    Ivonne Lourdes Mamani Velarde1, Iñigo Rúa-Figueroa2, Sara García Pérez1, Irene Altabás González3, CORAL Mourino Rodriguez4, Norman Jiménez5, JULIA MARTINEZ BARRIO6, Maria Galindo-Izquierdo7, Jaime Calvo- Alén8, Celia Eurasquin9, Belen Serrano Benavente10, Esther Uriarte Isacelaya11, Eva Tomero Muriel12, Mercedes Freire González13, Ricardo Blanco14, Eva Salgado-Pérez15, Paloma Vela16, Antonio Fernandez-Nebro17, Alejandro Olivé-Marqués18, Clara Sanguesa Gomez19, Javier Narvaez20, Raúl Menor-Almagro21, Jose Rosas22, José Ángel Hernández Beriain23, JAVIER MANERO24, Elena Aurrecoechea Aguinaga25, Oihane Ibarguengoitia-Barrena26, Carlos Montilla-Morales27, Gema Bonilla28, Vicente Torrente-Segarra29, Ana Paula Cacheda30, Maria J. García-Villanueva31, Clara Moriano Morales32, Concepción Fito Manteca33, Nuria Lozano Rivas34, Cristina Bohórquez35 and Jose-Maria Pego-Reigosa36, 1University Hospital of Vigo, Department of Rheumatology. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute (IISGS), Vigo, Spain, 2Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 3Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 4Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 5IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 6Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 7Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 8Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 9Department of Rheumatology, Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain, 10Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, 11Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 12Rheumatology, Hospital La Princesa, Madrid, Spain, 13Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 14Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 15Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, 16Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, 17Hospital Regional Universitario de Málaga, Malaga, Spain, 18Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 19Severo Ochoa Hospital, Madrid, Spain, 20Hospital Universitario de Bellvitge, Barcelona, Spain, 21Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 22Department of Rheumatology, Hospital Villajoyosa, Alicante, Spain, 23Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 24Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, 25Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 26Galdakao-Usansolo University Hospital, Bilbao, Spain, 27Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 28Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 29Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 30Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, 31Hospital Ramón y Cajal, Madrid, Spain, 32Rheumatology, Hospital Universitario de León, León, Spain, 33Complejo Universitario de Navarra, Pamplona, Spain, 34Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 35Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 36Rheumatology, Hospital do Meixoeiro, Vigo, Spain

    Background/Purpose: In systemic lupus erythematosus (SLE), there is no definition of states of moderate and severe SLE activity. How these states may influence different disease…
  • Abstract Number: 2476 • ACR Convergence 2023

    Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score

    Silvia Rosina1, Ana Isabel Rebollo Gimenez2, Letizia Tarantola1, Yulia Vyzhga1, Luca Carlini3, Elisa Patrone4, Maria Katsikas5, Claudia Saad-Magalhaes6, Dalia El-Ghoneimy7, Yasser El Miedany8, Raju Khubchandani9, Priyankar Pal10, Gabriele Simonini11, Giovanni Filocamo12, Maurizio Gattinara13, Fabrizio De Benedetti14, Davide Montin15, Adele Civino16, Muatasem Alsuweiti17, Valda Stenevicha18, Vyacheslav Chasnyk19, Ekaterina Alexeeva20, Sulaiman Al-Mayouf21, Soamarat Vilayuk22, Angela Pistorio23 and Angelo Ravelli24, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 3IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, 4IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy, 5Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, 6Sao Paulo State University, Botucatu, Brazil, 7PAIR Unit, Children's Hospital Ain Shams University, Cairo, Egypt, 8Ain Shams University, Italian Hospital St Abbassia, Cairo, Egypt, 9SRCC Childrens Hospital, Mumbai, India, 10Institute of Child Health, Pediatric Medicine, Kolkata, India, 11Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy, 12Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milan, Italy, 13Istituto Gaetano Pini, Divisione di Reumatologia, Milan, Italy, 14Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, 15Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy, 16P.O. Vito Fazzi, Uo Pediatria - Sezione Reumatologia e Immunologia Pediatrica, Lecce, Italy, 17King Hussein Medical Center, Department of Pediatrics, Amman, Jordan, 18Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, 19Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russia, 20Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 21King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, 22Mahidol University Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, 23Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 24Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…
  • Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium

    COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic

    Brooke Rezmer1, Michelle Adler2, Tamar Rubinstein3, Andrea Knight4 and Natoshia Cunningham5, 1Michigan State University College of Human Medicine, Grand Rapids, MI, 2Michigan State University, East Lansing, 3Children's Hospital at Montefiore, New York, NY, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Michigan State University, Grand Rapids, MI

    Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…
  • Abstract Number: 119 • 2023 Pediatric Rheumatology Symposium

    Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis

    Kaleo Ede1, Michael Shishov2, Elisa Wershba2, Nikita Goswami2, Sabrina Gorry2, Malin Jospeh2, Lucia Mirea2 and James O'neil2, 1Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, 2Phoenix Children's Hospital, Phoenix, AZ

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood, affecting 1 to 22 per 100,000 children. JIA-associated uveitis is known…
  • Abstract Number: 039 • 2023 Pediatric Rheumatology Symposium

    Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score

    Ana Isabel Rebollo-Giménez1, Yulia Vyzhga2, Luca Carlini3, Silvia Rosina4, Elisa Patrone1, Maria Katsikas5, Claudia Magalhaes6, Dalia El-Ghoneimy7, Yasser El Miedany8, Raju Khubchandani9, Priyankar Pal10, Gabriele Simonini11, Giovanni Filocamo12, Maurizio Gattinara13, Fabrizio De Benedetti14, Davide Montin15, Adele Civino16, Muatasem Alsuweiti17, Valda Stanevicha18, Vyacheslav Chasnyk19, Ekaterina Alexeeva20, Sulaiman M Al-Mayouf21, Soamarat Vilaiyuk22 and Angelo Ravelli23, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, 3IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, 4IRCCS Istituto Giannina Gaslini, Genova, Italy, 5Hospital de Pediatria Juan P. Garrahan, Department of Immunology/Rheumatology, Buenos Aires, Argentina, 6São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil, 7Children's Hospital, Ain Shams University, Pediatric Allergy, Immunology and Rheumatology Unit, Cairo, Egypt, 8Ain Shams University, Department of Rheumatology and Rehabilitation, Cairo, Egypt, 9Jaslok Hospital and Research Centre, Department of Paediatrics, Mumbai, India, 10Institute of Child Health, Pediatric medicine, Kolkata, India, Kolkata, India, 11IRCCS Meyer Children’s Hospital, Rheumatology Unit, Florence, Italy, 12Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milano, Italy, 13Istituto Gaetano Pini, Rheumatology Unit, Milano, Italy,, Genova, 14Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 15Regina Margherita Children Hospital, Immunology and Rheumatology Unit, Turin, Italy, 16Ospedale Vito Fazzi, Paediatric Immunology/Rheumatology Service, Lecce, Italy, 17King Hussein Medical Center, Department of Pediatrics - Pediatric Allergy, Immunology & Rheumatology Clinic, Amman, Jordan, 18University Children Hospital, Department of Pediatrics, Riga, Latvia, 19Saint-Petersburg State Pediatric Medical University, Department of Hospital Pediatrics, St. Petersburg, Russia, 20Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, 21King Faisal Specialist Hospital & Research Center, Alfaisal University, Department of Pediatric Rheumatology, Riyadh, Saudi Arabia, 22Mahidol University Faculty of Medicine, Ramathibodi Hospital Department of Pediatrics, Bangkok, Thailand, 23IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15% of all patients with JIA and is distinctfrom the other disease categories due to the…
  • Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium

    Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

    Gleice Clemente1, Maria Teresa Terreri2, Bruno Gualano3, Clovis Silva4 and Alexandre Wagner De Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de São Paulo, São Paulo, 4Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
  • Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium

    Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis

    Silvia Rosina1, Ana Isabel Rebollo-Giménez2, Letizia Tarantola3, Roberta Naddei4, Alessandro Consolaro2, Angela Pistorio5 and Angelo Ravelli6, 1IRCCS Istituto Giannina Gaslini, Genova, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, 3Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, 4Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, 5IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, 6IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy

    Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
  • Abstract Number: 065 • 2023 Pediatric Rheumatology Symposium

    Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA

    Meghana Karumuri1, Megan Quinlan-Waters2, Alexandra Duell2, Kelly Rogers2, Sheila Angeles-Han3 and Patricia Vega-Fernandez2, 1Michigan State University, Novi, MI, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Uncontrolled uveitis can lead to visual complications in 50% of children with JIA associated uveitis (JIA-U). While arthritis and uveitis are not considered to…
  • Abstract Number: 0387 • ACR Convergence 2022

    Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity

    Marta Ibañez Martinez1, Sonia Pastor Navarro2, Olga Compán Fernández2, Belén Miguel Ibáñez2, Ana Isabel Turrión Nieves2, Susana Gómez Castro1, Olga Martínez González2, Cristina Hidalgo Calleja2, Esther Toledano Martinez3 and Carlos Montilla Morales2, 1Hospital Universitario Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Spain, 3Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology